Dr. Carol joined the Foundation in August of 2020, where he oversees the brain program and contributes to reimbursement and regulatory related activities. Mark comes to the Foundation from SonaCare Medical, where he was CEO for six years. During his tenure, the company achieved FDA clearance in the US for its lead focused ultrasound technology for use in the treatment of prostate cancer, C- and CPT codes for the technology, and regulatory authorization in China and in many other countries around the world. Mark led efforts at SCM to bring FUS to play in the treatment of rectal cancer, kidney cancer, and peripheral vascular disease.
Prior to SCM, Mark spent 20 years in the field of radiation oncology where he was instrumental in several of the seminal developments in the field including intensity modulated radiation therapy, image-guided radiation therapy, and inverse treatment planning. Mark was trained as a neurosurgeon at the University of Maryland, later combining his training and technology bent in the early days of stereotactic radiation therapy and stereotaxis to develop innovations in frameless and image-guided stereotactic surgery. He received his BA with high honors as an Independent Scholar at Amherst College and his MD with Distinction in Research from the University of Rochester.